Recent Patents on CNS Drug Discovery 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders).
Authors: Malfitano AM
PMID: 27875961 [PubMed - in process] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - November 25, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.
Authors: Chicca A, Arena C, Manera C
Abstract
BACKGROUND: Anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are signalling lipids which belong to the class of endocannabinoids (ECs) and exert their actions by activating cannabinoid receptor type-1 (CB1) and type-2 (CB2). These receptors are involved in many physiological and pathological processes in the central nervous system (CNS) and in peripheral organs. Despite many potent and selective ligands for cannabinoid receptors have been generated over the last two decades, this class of compounds achieved only a very limited therapeutic success, mainly bec...
Source: Recent Patents on CNS Drug Discovery - September 19, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Endocannabionoid System in Neurological Disorders.
Authors: Bifulco M, Laezza C, Malfitano AM
Abstract
BACKGROUND: Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others.
METHODS: In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease and discuss the main findings about the use of cann...
Source: Recent Patents on CNS Drug Discovery - July 2, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.
Authors: Ranieri R, Marasco D, Laezza C, Bifulco M, Malfitano AM
Abstract
Cannabinoid receptors are involved in neurophatogenic mechanisms of inflammatory disorders of the central nervous system and their expression can be modulated during the disease. Brain inflammatory processes are characterized by infiltration of numerous types of cells, peripheral immune cells, brain resident immune cells, the microglial cells and numerous other neuronal cells. The disruption of the blood brain barrier favours cell infiltration in the central nervous system with consequent neuronal damage, common event in many neuro-i...
Source: Recent Patents on CNS Drug Discovery - June 25, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.
In this study, we focused on endocannabinoid mechanism of action in neuronal signaling and on cannabimimetic drug potential application in neurological disorders. Finally, novel patents on cannabis-based drugs with applicability in central nervous system disorders are highlighted, to suggest future potential therapeutic utility of derivatives of this ancient plant.
PMID: 27334611 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - June 25, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Neuropharmacological properties of Withania somnifera - Indian Ginseng: An overview on experimental evidence with emphasis on Clinical trials and patents.
CONCLUSION In order to realize the full therapeutic potential of WS extracts/its bioactives, systematic contemporary approaches such as bioinformatics, molecular docking studies, identification of specific gene targets as well as understanding the post-translational and epigenetic regulation of the various effects are necessary. Further, well designed clinical trials are required to exploit the neuromodulatory propensity of WS extract/bioactives in specific neurodegenerative diseases such as AD and PD.
PMID: 27316579 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - June 20, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Synthetic cannabinoid receptor agonists and antagonists: implication in CNS disorders.
CONCLUSIONS: The CB1 and CB2 receptor ligands offer several therapeutic opportunities for several CNS-related diseases. Based on the scientific literature, this review provides an overview of CB1 and CB2 receptor synthetic ligands obtained from drug research and in particular those synthesized for therapeutic purposes and potential clinical applications for central nervous system disorders.
PMID: 27193072 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - May 21, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Phytocannabinoids and cannabimimetic drugs: recent patents in central nervous system disorders.
CONCLUSIONS: Finally, although the study of the mechanisms of action of these compounds is still unsolved, many reports and patents strongly suggest therapeutic potential of these compounds in neurological diseases.
PMID: 27184693 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - May 18, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Peptide agonists and antagonists with potential application in neurological disorders.
CONCLUSIONS Peptide-based drug discovery is an important option to address common therapeutic challenges including human neurological diseases.
PMID: 27108811 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - April 27, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Immuno-modulatory Properties of a Quinolin-2-(1H)-on-3-carboxamide Derivative: Relevance in Multiple Sclerosis.
CONCLUSION: We reported similar effects of A2 in both cell types; however, a different mechanism of action might be suggested in cell from patients concerning cell activation and CB2 receptor expression. Overall, these data suggest an anti-inflammatory profile of A2 with potential implication in multiple sclerosis.
PMID: 27097974 [PubMed - as supplied by publisher] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - April 23, 2016 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy.
Authors: Sun MK
PMID: 26433978 [PubMed - in process] (Source: Recent Patents on CNS Drug Discovery)
Source: Recent Patents on CNS Drug Discovery - October 8, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Exosome-based strategies for diagnosis and therapy.
Authors: Urbanelli L, Buratta S, Sagini K, Ferrara G, Lanni M, Carla E
Abstract
Exosomes are small extracellular vesicles (30-120 nm) of endosomal origin, which are gaining the attention of the scientific community. Originally considered only a waste disposal system, they are now emerging as another class of signal mediators. Exosomes are secreted by any cell type and retrieved in every body fluid, such as blood, urine, saliva and amniotic liquid. Remarkably, their biochemical content includes not only lipids and proteins, but also nucleic acids, mainly miRNA and mRNA, with a few reports also indicating th...
Source: Recent Patents on CNS Drug Discovery - July 5, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Reperfusion Therapies in Acute Ischemic Stroke.
Authors: Yeo LL, Tan BY, Yee W, Amit K, Sharma VK
Abstract
Acute Ischemic stroke (IS) remains a leading cause of mortality and long-term disability. Owing to the time-constraints, only a fraction of acute IS patients receive the established and approved thrombolytic therapy and a sizeable proportion of acute IS stroke survivors remain permanently disabled. Rapid advances in various recanalization strategies have aimed at improving functional outcome and reducing mortality. Existing literature on various treatment approaches, including the evolution of various thrombolytic agents and interventional devices ...
Source: Recent Patents on CNS Drug Discovery - July 3, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Scientific prediction and prophetic patenting in drug discovery.
SCIENTIFIC PREDICTION AND PROPHETIC PATENTING IN DRUG DISCOVERY.
Recent Pat CNS Drug Discov. 2015 Jun 18;
Authors: Curry SH, Schneiderman A
Abstract
Pharmaceutical patenting involves writing claims based on both discoveries already made, and on prophesy of future developments in an ongoing project. This is necessitated by the very different timelines involved in the drug discovery and product development process on the one hand, and successful patenting on the other. If patents are sought too early there is a risk that patent examiners will disallow claims because of lack of enabl...
Source: Recent Patents on CNS Drug Discovery - June 20, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
Histamine H4 Receptor Antagonists: A New Approach for Tinnitus Treatment?
Authors: Hagenow J, Stark H
Abstract
Tinnitus, a disorder with disruptive sound perception in the head without an external source, affects around 15 % of the worldwide adult population. Since there is no approved drug for the treatment for this symptom, novel strategies need to be developed to provide relief for the patient. A patent from the small French start-up company Sensorion suggests the use of histamine H4 receptor (H4R) inhibitors as potential treatment. Since histamine and its receptor subtypes are strongly involved in neuronal and inflammatory processes in vestibular areas, targeting the H4R cou...
Source: Recent Patents on CNS Drug Discovery - April 27, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
